Cover Image
市場調查報告書

Sprint Bioscience AB的產品平台分析

Sprint Bioscience AB - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319994
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Sprint Bioscience AB的產品平台分析 Sprint Bioscience AB - Product Pipeline Review - 2015
出版日期: 2015年12月30日 內容資訊: 英文 24 Pages
簡介

Sprint Bioscience AB是總公司設立於製藥企業瑞典,利用癌症的代謝作用來開發治療藥。擁有癌症代謝作用、自吞噬作用、氨基酸代謝等朣瘤領域上的創新性標的之藥物開發平台。

本報告提供Sprint Bioscience AB 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Sprint Bioscience AB 基本資料

  • Sprint Bioscience AB 概要
  • 主要資訊
  • 企業資料

Sprint Bioscience AB :R&D概要

  • 主要的治療範圍

Sprint Bioscience AB :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Sprint Bioscience AB :開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Sprint Bioscience AB :藥物簡介

  • Small Molecule to Inhibit Choline Kinase for Cancer
  • Small Molecule to Inhibit MTH1 for Cancer
  • Small Molecule to Inhibit Vps34 for Triple Negative Breast Cancer
  • Small Molecule 1 for Cancer
  • Small Molecule to Inhibit PIP Kinase for Cancer
  • Small Molecules to Inhibit Tankyrases for Cancer

Sprint Bioscience AB :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Sprint Bioscience AB :最新的開發平台資訊

Sprint Bioscience AB :開發暫停中的計劃

Sprint Bioscience AB :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07932CDB

Summary

Global Markets Direct's, 'Sprint Bioscience AB - Product Pipeline Review - 2015', provides an overview of the Sprint Bioscience AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sprint Bioscience AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Sprint Bioscience AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Sprint Bioscience AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Sprint Bioscience AB's pipeline products

Reasons to buy

  • Evaluate Sprint Bioscience AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Sprint Bioscience AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Sprint Bioscience AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Sprint Bioscience AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sprint Bioscience AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Sprint Bioscience AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sprint Bioscience AB Snapshot
    • Sprint Bioscience AB Overview
    • Key Information
    • Key Facts
  • Sprint Bioscience AB - Research and Development Overview
    • Key Therapeutic Areas
  • Sprint Bioscience AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Sprint Bioscience AB - Pipeline Products Glance
    • Sprint Bioscience AB - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Sprint Bioscience AB - Drug Profiles
    • SB-01328
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-01683
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PIP4K2A for Leukemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Tankyrases for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sprint Bioscience AB - Pipeline Analysis
  • Sprint Bioscience AB - Pipeline Products by Target
  • Sprint Bioscience AB - Pipeline Products by Molecule Type
  • Sprint Bioscience AB - Pipeline Products by Mechanism of Action
  • Sprint Bioscience AB - Dormant Projects
  • Sprint Bioscience AB - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sprint Bioscience AB, Key Information
  • Sprint Bioscience AB, Key Facts
  • Sprint Bioscience AB - Pipeline by Indication, 2015
  • Sprint Bioscience AB - Pipeline by Stage of Development, 2015
  • Sprint Bioscience AB - Monotherapy Products in Pipeline, 2015
  • Sprint Bioscience AB - Out-Licensed Products in Pipeline, 2015
  • Sprint Bioscience AB - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Sprint Bioscience AB - Preclinical, 2015
  • Sprint Bioscience AB - Discovery, 2015
  • Sprint Bioscience AB - Pipeline by Target, 2015
  • Sprint Bioscience AB - Pipeline by Molecule Type, 2015
  • Sprint Bioscience AB - Pipeline Products by Mechanism of Action, 2015
  • Sprint Bioscience AB - Dormant Developmental Projects,2015

List of Figures

  • Sprint Bioscience AB - Pipeline by Top 10 Indication, 2015
  • Sprint Bioscience AB - Pipeline by Stage of Development, 2015
  • Sprint Bioscience AB - Monotherapy Products in Pipeline, 2015
  • Sprint Bioscience AB - Pipeline by Top 10 Target, 2015
  • Sprint Bioscience AB - Pipeline by Top 10 Molecule Type, 2015
  • Sprint Bioscience AB - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top